Full Text
PCN58 A COST UTILITY ANALYSIS OF ERLOTINIB IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)

Abstract

Authors

PA Bradbury R Jang P Isogai R Ng N Mittmann W Evans FA Shepherd NB Leighl

Back to Volume 11, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×